Sulfide alkyl compounds for HBV treatment

Patent metadata

Field	Value
Publication number	US-10710959-B2
Application number	US-201816235167-A
Country	US
Kind code	B2
Filing date	Dec 28, 2018
Priority date	Dec 2, 2014
Publication date	Jul 14, 2020
Grant date	Jul 14, 2020

Abstract

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

First claim

The invention claimed is:

1. A compound
selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, further comprising at least one pharmaceutically acceptable carrier.

3. A method of treating an HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound according to claim 1 .

4. The method of claim 3 , further comprising administering to the individual at least one additional therapeutic agent selected from the group consisting of an HBV vaccine, HBV polymerase inhibitor, interferon, pegylated interferon, viral entry inhibitor, viral maturation inhibitor, BAY 41-4109, reverse transcriptase inhibitor, a TLR-agonist, AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), and a combination thereof.

5. The method of claim 4 , wherein the pegylated interferon is pegylated interferon alpha (IFN-α), pegylated interferon lambda (IFN-λ), or pegylated interferon gamma (IFN-γ).

6. The method of claim 4 , wherein the reverse transcriptase inhibitor is at least one of Zidovudine, Didanosine, Zalcitabine, ddA, Stavudine, Lamivudine, Abacavir, Emtricitabine, Entecavir, Apricitabine, Atevirapine, ribavirin, acyclovir, famciclovir, valacyclovir, ganciclovir, valganciclovir, Tenofovir, Adefovir, cidofovir, Efavirenz, Nevirapine, Delavirdine, or Etravirine.

7. The method of claim 4 , wherein the TLR-agonist is selected from the group consisting of SM360320 (9-benzyl-8-hydroxy-2-(2-methoxy-ethoxy)adenine) and AZD 8848 (methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl][3-(4-morpholinyl) propyl]amino}methyl)phenyl]acetate).

8. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignees

• Novira Therapeutics Inc

Inventors

• Chen Austin
• Bravo Yalda
• Stock Nicholas
• Pedram Bijan
• Jacintho Jason
• Clark Ryan C

Classifications

• A61K31/5375 Primary

  1,4-Oxazines, e.g. morpholine · CPC title

• A61K31/192

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• C07D295/192

  from aromatic carboxylic acids · CPC title

• C07D213/81

  Amides; Imides · CPC title